<DOC>
	<DOC>NCT01888744</DOC>
	<brief_summary>The aim of our study is to define the optimal ovarian stimulation protocol concerning PGD and for this reason we plan a randomized controlled trial (RCT) comparing gonadotropin-releasing hormone (GnRH) agonist protocol versus GnRH antagonist protocol. The follicle stimulating hormone (FSH) preparation in both arms will be highly purified FSH (Menopur®).</brief_summary>
	<brief_title>Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist</brief_title>
	<detailed_description>Patients will be randomized at the outpatient clinic in two groups.</detailed_description>
	<mesh_term>Chorionic Gonadotropin</mesh_term>
	<mesh_term>Triptorelin Pamoate</mesh_term>
	<mesh_term>Menotropins</mesh_term>
	<mesh_term>Buserelin</mesh_term>
	<mesh_term>Deslorelin</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Ganirelix</mesh_term>
	<criteria>≤ 39 years the day of oocyte retrieval BMI ≤ 29 cycle rank 1 menstrual cycle 2536 days PGD or preimplantation genetic screening (PGS) requested ICSI Single embryo transfer (SET) on day 5 Polycystic Ovary Syndrome (PCOS) (according Rotterdam criteria) Hormonal disturbances Endometriosis grade III and IV</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Intracytoplasmic sperm injection (ICSI)</keyword>
	<keyword>PGD</keyword>
	<keyword>GnrH agonist</keyword>
	<keyword>GnRH antagonist</keyword>
</DOC>